XML 31 R43.htm IDEA: XBRL DOCUMENT v3.20.1
Significant Agreements - Other Agreements (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2019
May 31, 2014
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2004
Significant Agreements          
Milestones and fees     $ 37,663,000 $ 32,771,000  
License agreement with antibody technology company          
Significant Agreements          
Milestones and fees     0 200,000  
License agreement with antibody technology company | Additional Research Fees          
Significant Agreements          
Collaborative arrangement amount paid and expensed   $ 300,000      
License Agreement With Fulcrum Therapeutics          
Significant Agreements          
Milestones and fees     300,000 0  
License Agreement With Fulcrum Therapeutics | Additional Research Fees          
Significant Agreements          
Collaborative arrangement amount paid and expensed $ 10,000,000.0        
License Agreement With Fulcrum Therapeutics | Additional Research Fees | Maximum          
Significant Agreements          
Total potential milestone payments (up to) 143,500,000        
License Agreement With Fulcrum Therapeutics | Research, Development and Commercial Milestone Payments | Maximum          
Significant Agreements          
Total potential milestone payments (up to) $ 295,000,000.0        
Non-collaborative Arrangement Transactions | Sotarcept | Development milestone | Maximum          
Significant Agreements          
Total potential milestone payments (up to)         $ 2,000,000.0
Non-collaborative Arrangement Transactions | REBLOZYL Agreement | Development milestone | Maximum          
Significant Agreements          
Total potential milestone payments (up to)         $ 700,000
Non-collaborative Arrangement Transactions | License Agreement with Non Profit Institution          
Significant Agreements          
Milestones and fees     $ 300,000 $ 0  
Non-collaborative Arrangement Transactions | License Agreement with Non Profit Institution | Maximum          
Significant Agreements          
Milestone fees payable as percentage of research and U.S. development progress and sublicensing revenue         25.00%
Royalty payable as percentage of net sales         3.50%
Non-collaborative Arrangement Transactions | License Agreement with Non Profit Institution | Minimum          
Significant Agreements          
Milestone fees payable as percentage of research and U.S. development progress and sublicensing revenue         10.00%
Royalty payable as percentage of net sales         1.00%